ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Pfizer & Lilly's non-opioid drug reduces pain in osteoarthritis
October 25, 2018Pfizer and Eli Lilly have announced data revealing that their nerve growth factor (NGF) inhibitor tanezumab met all three of its co-primary endpoints in the treatment of osteoarthritis (OA). -
Skovronsky to take over Lilly Research Labs as Lundberg retires
September 30, 2017After eight years at Eli Lilly and heading up its Lilly Research Labs unit, Jan Lundberg, Ph.D., will retire next May as Dan Skovronsky, M.D., Ph.D., will be promoted to replace him. -
Pfizer and Lilly receive FDA Fast Track designation for tanezumab
June 14, 2017Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for tanezumab for the treatment of chronic pain in patients with osteoarthritis (OA) and chroni
Pharma Sources Insight January 2025
